On May 4, 2026, the South Korean KOSDAQ market witnessed a dramatic divergence among medical artificial intelligence (AI) stocks, with some companies plummeting and others managing to eke out gains. Investors, analysts, and industry watchers were left parsing the numbers, trying to make sense of what appeared to be a market split right down the middle.
According to CBC News, the day was anything but ordinary for those tracking the medical AI sector. Vuno, often cited as a bellwether for Korea’s medical AI industry, saw its stock tumble by 1,710 KRW, closing at 17,250 KRW—a staggering drop of about 9%. The stock hit an intraday low of 17,110 KRW, as selling pressure mounted and investors rushed to realize recent gains. LabGenomics, another notable player in the space, declined by 51 KRW (down 3.84%) to finish at 1,277 KRW, while Noeul’s shares dropped by 88 KRW (down 5.68%) to 1,460 KRW. Rokit Healthcare, a company that has drawn significant attention for its innovations, also joined the downward trend, falling by 5,000 KRW (down 6.54%) to close at 71,500 KRW.
The reasons behind this sharp selloff, as reported by CBC News, appear to be twofold: a wave of profit-taking after rapid short-term rallies and a temporary cooling of investor sentiment toward the medical AI sector. The market had seen a flurry of activity in recent weeks, with several stocks surging on the back of technological breakthroughs and positive earnings reports. However, as is often the case in volatile sectors, those gains proved fragile when investors decided it was time to lock in profits.
Yet, the story of May 4 wasn’t just about decline. In a striking contrast, some stocks managed to buck the broader trend and post gains, albeit modest ones. Acryl, for instance, rose by 2,000 KRW (up 5.15%) to finish at 40,800 KRW. Deepnoid also edged up by 30 KRW (up 0.83%) to close at 3,630 KRW. Lunit, another company in the medical AI field, managed a slight gain of 50 KRW (up 0.24%) to end at 20,800 KRW. What stood out with Lunit was its pronounced volatility; the stock traded between a low of 20,500 KRW and a high of 26,450 KRW during the day, with trading volume surpassing 2.2 million shares. This level of activity suggested that institutional investors and short-term traders were actively picking their spots, leading to a highly selective market environment.
The divergence in stock performance highlighted a broader trend in the medical AI sector: the days of blanket optimism and sector-wide rallies may be over, replaced by a more nuanced approach where investors scrutinize each company’s technological prowess and business execution. As CBC News put it, “The medical AI sector is at a stage where stock prices are influenced by both technology expectations and performance verification, leading to differentiated stock price movements based on individual company results.”
Turning a closer eye to Rokit Healthcare, the story gets even more interesting. According to JoongAng Economy News, as of 9:37 AM on May 4, 2026, Rokit Healthcare’s shares were trading at 75,800 KRW, down 0.92% from the previous day’s close of 76,500 KRW. The stock opened at 75,500 KRW and fluctuated between a low of 73,200 KRW and a high of 76,400 KRW, marking a price swing of 3,200 KRW. The trading volume reached 87,910 shares, with a total trading value of approximately 6.552 billion KRW. Rokit Healthcare’s market capitalization stood at roughly 1.1898 trillion KRW, placing it 114th among KOSDAQ-listed companies.
What’s particularly notable is the role of foreign investors. Out of Rokit Healthcare’s total of 15,738,739 listed shares, foreign investors held 171,416 shares, accounting for just 1.09% of the total. This relatively low foreign ownership may suggest that, despite its market cap and technological promises, the company’s appeal remains largely domestic for now.
The previous trading day, May 3, 2026, had seen Rokit Healthcare open at 82,200 KRW, hit a high of 82,300 KRW, dip to a low of 76,000 KRW, and close at 76,500 KRW, with a significantly higher trading volume of 256,370 shares. The sharp drop in both price and volume the following day pointed to a cooling off after a period of intense activity, consistent with the broader narrative of profit-taking and shifting sentiment.
When compared to the sector’s average movement—where the medical AI industry as a whole showed a 2.71% gain on the same day—Rokit Healthcare’s performance looked comparatively weak. This underperformance raises questions about whether the company’s fundamentals or recent news may have spooked investors. However, no single factor appeared to be at play; rather, the day’s market action seemed to reflect a mix of technical trading, sector rotation, and a search for the next big winner in a rapidly evolving field.
For investors, the message was clear: the medical AI sector is entering a new phase where not all boats rise with the tide. Instead, companies are being judged on their individual merits—be it their technological capabilities, commercialization success, or their ability to deliver on the lofty promises that have fueled so much excitement in recent years. As CBC News noted, “This indicates that selective inflows of institutional and short-term funds are leading to a differentiated market by stock.” In other words, investors are picking favorites, and the winners and losers are being decided on a case-by-case basis.
It’s also worth noting the caution advised by the media. Both CBC News and JoongAng Economy News stressed that the information provided was for general news purposes only and not intended as investment advice. They reminded readers that “stocks are highly volatile and losses are the responsibility of the investor,” urging anyone considering a move in this space to seek professional guidance and conduct thorough research before making any decisions.
The events of May 4, 2026, serve as a vivid reminder of the unpredictability and excitement inherent in cutting-edge sectors like medical AI. For now, the market seems to be telling investors: do your homework, pick your spots, and don’t expect easy answers. The era of indiscriminate gains may be over, but for those willing to dig deep and separate hype from substance, opportunities—and risks—abound.